<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="t1-dic-2020-4-15" position="float">
 <label>Table 1</label>
 <caption>
  <p>Potential treatments for patient with COVID-19.</p>
 </caption>
 <table frame="box" rules="all">
  <thead>
   <tr>
    <th valign="bottom" align="left" rowspan="1" colspan="1">Therapies</th>
    <th valign="bottom" align="left" rowspan="1" colspan="1">Dosage
     <xref ref-type="table-fn" rid="tfn1-dic-2020-4-15">*</xref>
    </th>
    <th valign="bottom" align="left" rowspan="1" colspan="1">Side effects</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td colspan="3" valign="top" align="left" rowspan="1">
     <italic>Antivirals</italic>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Remdesivir (nucleotide analogue)
     <xref rid="b50-dic-2020-4-15" ref-type="bibr">50</xref>,
     <xref rid="b51-dic-2020-4-15" ref-type="bibr">51</xref>,
     <xref rid="b110-dic-2020-4-15" ref-type="bibr">110</xref>,
     <xref rid="b111-dic-2020-4-15" ref-type="bibr">111</xref>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">Adult: loading dose 200 mg IV on day 1, followed by 100 mg IV once-daily maintenance doses for 9 days</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Increased hepatic enzymes
     <break/>Diarrhoea
     <break/>Rash
     <break/>Renal impairment
     <break/>Hypotension
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Lopinavir–ritonavir (protease inhibitor)
     <xref rid="b54-dic-2020-4-15" ref-type="bibr">54</xref>,
     <xref rid="b56-dic-2020-4-15" ref-type="bibr">56</xref>,
     <xref rid="b59-dic-2020-4-15" ref-type="bibr">59</xref>,
     <xref rid="b66-dic-2020-4-15" ref-type="bibr">66</xref>,
     <xref rid="b110-dic-2020-4-15" ref-type="bibr">110</xref>,
     <xref rid="b112-dic-2020-4-15" ref-type="bibr">112</xref>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">Adult: 500 mg orally once to twice daily for 10–14 days</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Gastrointestinal intolerance
     <break/>Hepatotoxicity
     <break/>Pancreatitis
     <break/>QT prolongation
     <break/>Lipid elevation
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Chloroquine
     <xref rid="b110-dic-2020-4-15" ref-type="bibr">110</xref>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">Adult: 400 mg PO daily for 5 days</td>
    <td rowspan="2" valign="top" align="left" colspan="1">QT prolongation
     <break/>Nausea and vomiting
     <break/>Retinopathy
     <break/>Rash
     <break/>Hypoglycaemia
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Hydroxychloroquine sulfate
     <xref rid="b64-dic-2020-4-15" ref-type="bibr">64</xref>,
     <xref rid="b113-dic-2020-4-15" ref-type="bibr">113</xref>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">Adult: 400 mg PO every 12 hours for 1 day, then 200 mg PO every 12 hours for 4 days.</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Protease inhibitor
     <xref rid="b76-dic-2020-4-15" ref-type="bibr">76</xref>,
     <xref rid="b114-dic-2020-4-15" ref-type="bibr">114</xref>–
     <xref rid="b116-dic-2020-4-15" ref-type="bibr">116</xref>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">Nelfinavir, camostat mesilate, ritonavir, danoprevir, darunavir, flavopiridol, relacatib PO</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Lipodystrophy
     <break/>Metabolic effects
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Nucleoside analogue
     <xref rid="b76-dic-2020-4-15" ref-type="bibr">76</xref>,
     <xref rid="b117-dic-2020-4-15" ref-type="bibr">117</xref>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">Galidesivir IV</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Nephrotoxicity
     <break/>Myopathy
     <break/>Mitochondrial toxicity
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Fusion inhibitor
     <xref rid="b76-dic-2020-4-15" ref-type="bibr">76</xref>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">Umifenovir PO</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Safety profile not established, ongoing clinical trial</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">RNA polymerase inhibitor
     <xref rid="b76-dic-2020-4-15" ref-type="bibr">76</xref>,
     <xref rid="b116-dic-2020-4-15" ref-type="bibr">116</xref>,
     <xref rid="b118-dic-2020-4-15" ref-type="bibr">118</xref>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">Favipiravir PO</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Safety profile not established, ongoing clinical trial</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Neuraminidase inhibitor
     <xref rid="b76-dic-2020-4-15" ref-type="bibr">76</xref>,
     <xref rid="b119-dic-2020-4-15" ref-type="bibr">119</xref>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">Oseltamivir PO</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Gastrointestinal side effects
     <break/>Headache
    </td>
   </tr>
   <tr>
    <td colspan="3" valign="top" align="left" rowspan="1">
     <italic>Pharmacological therapies targeting the immune system</italic>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Corticosteroids
     <xref rid="b66-dic-2020-4-15" ref-type="bibr">66</xref>,
     <xref rid="b77-dic-2020-4-15" ref-type="bibr">77</xref>,
     <xref rid="b110-dic-2020-4-15" ref-type="bibr">110</xref>,
     <xref rid="b120-dic-2020-4-15" ref-type="bibr">120</xref>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">Adult: methylprednisolone 40 mg IV every 12 hours for 5 days or 1–2 mg/kg/day IV for 7 days</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Osteonecrosis
     <break/>Osteoporosis
     <break/>Psychosis
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Convalescent plasma
     <xref rid="b82-dic-2020-4-15" ref-type="bibr">82</xref>,
     <xref rid="b87-dic-2020-4-15" ref-type="bibr">87</xref>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">No references</td>
    <td valign="top" align="left" rowspan="1" colspan="1">No significant side effects</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Tocilizumab (monoclonal antibodies)
     <xref rid="b66-dic-2020-4-15" ref-type="bibr">66</xref>,
     <xref rid="b121-dic-2020-4-15" ref-type="bibr">121</xref>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">4–8 mg/kg (max 800 mg/dose)
     <break/>IV
     <break/>Doses may be repeated 12 hours later if the initial dose is not effective
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">Gastrointestinal perforation
     <break/>Anaemia
     <break/>Hepatitis
     <break/>Infusion reaction
     <break/>Neutropenia
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn id="tfn1-dic-2020-4-15">
   <label>*</label>
   <p>Suggested dosages are adapted from the proposed dose to treat COVID-19 from ongoing clinical trials; the efficacy and safety have not been verified by authors.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
